Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytogenetics and experimental models

J A Toretsky1, L J Helman

  • 1University of Maryland Medical Center, Baltimore 21201, USA.

Current Opinion in Oncology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm.

Journal of molecular biology·2018
Same author

Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.

Oncogene·2013
Same author

Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.

Oncogene·2013
Same author

Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2012
Same author

Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Oncogene·2011
Same author

Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).

Oncogene·2010
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Cytogenetic analysis improves sarcoma diagnosis and classification by identifying characteristic tumor-specific chromosomal translocations. Advances in technology and understanding genetic alterations offer future therapeutic potential.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Cytogenetics has significantly advanced sarcoma diagnosis and classification.
  • Many major sarcomas exhibit characteristic tumor-specific chromosomal translocations crucial for diagnosis.

Purpose of the Study:

  • To review the role of cytogenetics in sarcoma diagnosis and classification.
  • To discuss the emergence of genetic alterations as prognostic factors.
  • To highlight laboratory applications derived from cytogenetic and genetic abnormalities.

Main Methods:

  • Review of current literature on cytogenetics in sarcoma.
  • Analysis of tumor-specific chromosomal translocations.
  • Discussion of emerging technologies like spectral karyotyping.

Related Experiment Videos

  • Examination of genetic alterations as prognostic indicators.

    • Main Results:

    • Identification of characteristic tumor-specific chromosomal translocations aids sarcoma diagnosis.
    • Discovery of related translocations in subsets of Ewing's family of tumors and myxoid liposarcomas.
    • Emerging genetic alterations (e.g., p53 expression) show prognostic value in various sarcomas.

    Conclusions:

    • Cytogenetic advances are critical for accurate sarcoma diagnosis and classification.
    • Genetic alterations are increasingly recognized as important prognostic factors.
    • Future therapeutic advances are anticipated through improved diagnosis, prognosis, and modeling based on cytogenetic and genetic findings.